

Table S1 The search strategy summary for clinicaltrials.gov

Items	Specification
Date of search	August 31, 2023
Databases and other sources searched	Clinicaltrials.gov
Search terms used	“Antibody-drug conjugate (under the treatment/intervention)”, “phase 1–4 (under study phase)”, “with results (under study results)”
Timeframe	Up to August 31, 2023
Inclusion and exclusion criteria	Inclusion criteria: ADCs that were either FDA-approved or still being actively studied by the sponsor Exclusion criteria: ADCs that had been discontinued for further development by the sponsor
Selection process	Conducted by first author, consensus by both authors

FDA, United States Food and Drug Administration; ADC, antibody-drug conjugate.

Table S2 The search strategy summary for additional studies in drugs in development

Items	Specification
Date of search	August 31, 2023
Databases and other sources searched	Google.com
Search terms used	[["FDA approved antibody drug conjugates"]] OR[" gemtuzumab ozogamicin"] OR [" brentuximab vedotin"] OR ["ado-trastuzumab emtansine"] OR ["inotuzumab ozogamicin"] OR ["polatuzumab vedotin"] OR [" trastuzumab deruxtecan"] OR ["enfortumab vedotin"] OR ["sacituzumab govitecan"]OR[" loncastuximab tesirine"] OR ["tisetumab vedotin"] OR ["moxetumomab pasudotox"] OR ["mirvetuximab soravtansine"] OR[" belantamab mafodotin"] OR [" patritumab deruxtecan"] OR ["datopotomab deruxtecan"] OR[" telisotuzumab vedotin"] OR ["ARX788"] OR ["antibody drug conjugate older patients"]
Timeframe	Up to August 31, 2023
Inclusion and exclusion criteria	Inclusion criteria: ADCs that were either FDA-approved or still being actively studied by the sponsor. Abstracts regarding the ADC from previous oncology conferences (i.e., American Society of Clinical Oncology Annual Meeting) Exclusion criteria: ADCs that had been discontinued for further development by the sponsor. Findings already found in previous search
Selection process	Conducted by first author, consensus by both authors

FDA, United States Food and Drug Administration; ADC, antibody-drug conjugate.